Brainomix Raises £4.8m in Series C Extension, Bringing Total to £18.8m

Why It Matters

The funding accelerates Brainomix’s market penetration in the high‑growth AI‑healthcare sector, potentially improving treatment speed for stroke patients and early detection of pulmonary fibrosis.

Key Takeaways

• £4.8m added to Series C, total £18.8m
• Funding targets US expansion of FDA‑cleared AI tools
• Brainomix 360 Stroke automates acute stroke imaging assessment
• e‑Lung AI predicts pulmonary fibrosis progression

Pulse Analysis

Artificial intelligence is reshaping diagnostic radiology, with rapid‑read imaging becoming a decisive factor in acute care pathways. Brainomix’s platforms—Brainomix 360 Stroke for instant stroke assessment and e‑Lung for quantifying fibrotic lung disease—address two of the most time‑sensitive clinical challenges. By embedding deep‑learning algorithms directly into CT workflows, these tools reduce manual interpretation, shorten door‑to‑treatment times, and generate quantitative biomarkers that support evidence‑based decisions, aligning with hospitals’ push toward value‑based care.

The fresh £4.8 million injection, bringing the Series C to £18.8 million, signals strong investor confidence in AI‑enabled imaging as a scalable revenue engine. Led by Parkwalk Advisors and Hostplus, and bolstered by Modi Ventures, the round earmarks resources for U.S. market expansion, where regulatory clearance and reimbursement pathways are increasingly favorable for AI diagnostics. This capital will fund sales teams, integration services, and localized clinical validation, positioning Brainomix to compete with larger med‑tech firms while leveraging its Oxford research pedigree. The move also diversifies its geographic risk, tapping into a fragmented U.S. hospital ecosystem that values turnkey, FDA‑cleared solutions.

Looking ahead, broader adoption of Brainomix’s technology could shift clinical standards for stroke triage and pulmonary fibrosis monitoring. Faster stroke imaging translates into higher rates of endovascular thrombectomy, directly improving patient survival and functional outcomes. In pulmonary fibrosis, early AI‑driven detection may enable timely antifibrotic therapy, potentially slowing disease progression. As payers increasingly reward outcomes over volume, AI platforms that demonstrably enhance efficiency and clinical results are poised for accelerated uptake, making Brainomix a noteworthy player in the next wave of digital health transformation.

Deal Summary

Oxford‑based AI imaging firm Brainomix announced a £4.8 million extension to its Series C round, taking the total to £18.8 million. The new funding, led by existing investors Parkwalk Advisors and Hostplus (via the IP Group Hostplus Innovation Fund) and joined by new investor Modi Ventures, will support the expansion of its US operations and rollout of its Brainomix 360 Stroke and e‑Lung platforms.